Lung Cancer
Volume 67, Issue 2 , Pages 127-135 , February 2010

Methodological aspects of lung cancer clinical trials in the era of targeted agents

  • Massimo Di Maio

      Affiliations

    • Clinical Trials Unit, National Cancer Institute, Napoli, Italy
    • ,
  • Ciro Gallo

      Affiliations

    • Department of Medicine and Public Health, Second University of Napoli, Italy
    • ,
  • Ermelinda De Maio

      Affiliations

    • Clinical Trials Unit, National Cancer Institute, Napoli, Italy
    • ,
  • Alessandro Morabito

      Affiliations

    • Clinical Trials Unit, National Cancer Institute, Napoli, Italy
    • ,
  • Maria Carmela Piccirillo

      Affiliations

    • Clinical Trials Unit, National Cancer Institute, Napoli, Italy
    • ,
  • Cesare Gridelli

      Affiliations

    • Division of Medical Oncology, “S. Giuseppe Moscati” Hospital, Avellino, Italy
    • ,
  • Francesco Perrone

      Affiliations

    • Clinical Trials Unit, National Cancer Institute, Napoli, Italy
    • Corresponding Author InformationCorresponding author at: Clinical Trias Unit, National Cancer Institute – “G.Pascale” Foundation, Via Mariano Semmola, 80131 Napoli, Italy. Tel.: +39 081 5903571; fax: +39 081 7702938.

Received 27 January 2009 ,Revised 28 September 2009 ,Accepted 1 October 2009.

References 

  1. Hoang T, Schiller JH. Advanced NSCLC: from cytotoxic systemic chemotherapy to molecularly targeted therapy. Expert Rev Anticancer Ther. 2002;2:393–401
  2. Von Hoff DD. There are no bad anticancer agents, only bad clinical trial designs—twenty-first Richard and Hinda Rosenthal Foundation Award Lecture. Clin Cancer Res. 1998;4:1079–1086
  3. Eisenhauer EA. Phase I and II trials of novel anti-cancer agents: endpoints, efficacy and existentialism. The Michel Clavel Lecture, held at the 10th NCI-EORTC Conference on New Drugs in Cancer Therapy, Amsterdam, 16–19 June 1998. Ann Oncol. 1998;9:1047–1052
  4. Seymour L. The design of clinical trials for new molecularly targeted compounds: progress and new initiatives. Curr Pharm Des. 2002;8:2279–2284
  5. Fox E, Curt GA, Balis FM. Clinical trial design for target-based therapy. Oncologist. 2002;7:401–409
  6. Suman VJ, Dueck A, Sargent DJ. Clinical trials of novel and targeted therapies: endpoints, trial design, and analysis. Cancer Invest. 2008;26:439–444
  7. Rubinstein L, Crowley J, Ivy P, Leblanc M, Sargent D. Randomized Phase II designs. Clin Cancer Res. 2009;15:1883–1890
  8. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47:207–214
  9. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumor. J Natl Cancer Inst. 2000;92:205–216
  10. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–247
  11. Perrone F, Di Maio M, De Maio E, Maione P, Ottaiano A, Pensabene M, et al. Statistical design in phase II trials and its application in breast cancer. Lancet Oncol. 2003;4:305–311
  12. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small cell lung cancer. N Engl J Med. 2005;353:123–132
  13. Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung cancer). Lancet. 2005;366:1527–1537
  14. Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, Wu YL, et al. Gefitinib versus docetaxel in previously treated (INTEREST): a randomized phase III trial. Lancet. 2008;372:1809–1818
  15. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. SHARP Investigators Study Group: sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–390
  16. Stone A, Wheeler C, Carroll K, Barge A. Optimizing randomized phase II trial assessing tumor progression. Contemp Clin Trials. 2007;28:146–152
  17. Giaccone G, Gallegos Ruiz M, Le Chevalier T, Thatcher N, Smit E, Rodriguez JA, et al. Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study. Clin Cancer Res. 2006;12:6049–6055
  18. Zhou X, Liu S, Kim ES, Herbst RS, Lee JJ. Bayesian adaptive design for targeted therapy development in lung cancer—a step toward personalized medicine. Clin Trials. 2008;5:181–193
  19. Stone A, Wheeler C, Barge A. Improving the design of phase II trials of cytostatic anticancer agents. Contemp Clin Trials. 2007;28:138–145
  20. Mick R, Crowley JJ, Carroll RJ. Phase II clinical trial design for noncytotoxic anticancer agents for which time to disease progression is the primary endpoint. Control Clin Trials. 2000;21:343–359
  21. Gridelli C, Morabito A, Gebbia V, Mencoboni M, Carrozza F, Viganò MG, et al. Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: the cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomized phase II trials. Lung Cancer. 2009;April 18 [Epub ahead of print]
  22. Lee JJ, Feng L. Randomized phase II designs in cancer clinical trials: current status and future directions. J Clin Oncol. 2005;23:4450–4457
  23. Rubinstein LV, Korn EL, Freidlin B, Hunsberger S, Ivy SP, Smith MA. Design issues of randomized phase II trials and a proposal for phase II screening trials. J Clin Oncol. 2005;23:7199–7206
  24. Jung SH. Randomized phase II trials with a prospective control. Stat Med. 2008;27:568–583
  25. Simon RM, Steinberg SM, Hamilton M, Hildesheim A, Khleif S, Kwak LW, et al. Clinical trial designs for the early clinical development of therapeutic cancer vaccines. J Clin Oncol. 2001;19:1848–1854
  26. Korn EL, Arbuck SG, Pluda JM, Simon R, Kaplan RS, Christian MC, et al. Clinical trial designs for cytostatic agents: are new approaches needed?. J Clin Oncol. 2001;19:265–272
  27. Ratain MJ, Karrison TG. Testing the wrong hypothesis in phase II oncology trials: there is a better alternative. Clin Cancer Res. 2007;13:781–782
  28. Heymach JV, Johnson BE, Prager D, Csada E, Roubec J, Pesek M, et al. Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. J Clin Oncol. 2007;25:4270–4277[Erratum in: J Clin Oncol 2008; 26: 165–6]
  29. Heymach JV, Paz-Ares L, De Braud F, Sebastian M, Stewart DJ, Eberhardt WE, et al. Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol. 2008;26:5407–5415
  30. Herbst RS, Sun Y, Korfee S, Germonpré P, Saijo N, Zhou C, et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): a randomized, double-blind phase III trial (ZODIAC). J Clin Oncol. 2009;27:18s;[suppl.; abstr. CRA8003]
  31. Kopec JA, Abrahamowicz M, Esdaile JM. Randomized discontinuation trials: utility and efficiency. J Clin Epidemiol. 1993;46:959–971
  32. Rosner GL, Stadler W, Ratain MJ. Randomized discontinuation design: application to cytostatic antineoplastic agents. J Clin Oncol. 2002;20:4478–4484
  33. Capra WB. Comparing the power of the discontinuation design to that of the classic randomized design on time-to-event endpoints. Control Clin Trials. 2004;25:168–177
  34. Schiller JH, Lee JW, Hanna NH, Traynor AM, Carbone DP. A randomized discontinuation phase II study of sorafenib versus placebo in patients with non-small cell lung cancer who have failed at least two prior chemotherapy regimens: E2501. J Clin Oncol. 2008;26:[May 20 suppl.; abstr. 8014]
  35. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol. 2009;27:1227–1234
  36. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel–carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542–2550
  37. Johnson KR, Ringland C, Stokes BJ, Anthony DM, Freemantle N, Irs A, et al. Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis. Lancet Oncol. 2006;7:741–746
  38. Perrone F. Don’t forget survival, please…. Lancet Oncol. 2006;7:703–704
  39. Di Maio M, Bria E, Rossi A, Perrone F. Progression-free survival as primary end point in advanced non-small-cell lung cancer: does the size matter?. Ann Oncol. 2008;19:402–403
  40. Manegold C, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, et al. on behalf of the AVAiL study group. BO17704 (AVAiL): a phase III randomised study of first-line bevacizumab combined with cisplatin/gemcitabine in patients with advanced or recurrent non-squamous, non-small-cell-lung cancer”. Ann Oncol 2008; 19 (suppl. 8): viii1—Abstract Book of the 33rd European Society of Medical Oncology Congress, Stockholm, Sweden 12–16 September 2008 [abstr. LBA1].
  41. Norton L. Discussion. Clinical Trials. 2007;4:173–175
  42. Sargent DJ, Conley BA, Allegra C, Collette L. Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol. 2005;23:2020–2027
  43. Hoering A, Leblanc M, Crowley JJ. Randomized phase III clinical trial designs for targeted agents. Clin Cancer Res. 2008;14:4358–4367
  44. Brookes ST, Whitley E, Peters TJ, Mulheran PA, Egger M, Davey Smith G. Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives. Health Technol Assess. 2001;5:1–56
  45. Freidlin B, Simon R. Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients. Clin Cancer Res. 2005;11:7872–7878
  46. Simon R, Maitournam A. Perspective evaluating the efficiency of targeted designs for randomized clinical trials. Clin Can Res. 2004;10:6759–6763
  47. Maitournam A, Simon R. On the efficiency of targeted clinical trials. Stat Med. 2005;24:329–339
  48. Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczesna A, Juhasz E, et al., on behalf of the SATURN Investigators. SATURN: a double-blind, randomized, phase III study of maintenance erlotinib versus placebo following non-progression with first-line platinum-based chemotherapy in patients with advanced NSCLC. J Clin Oncol 27:15s, 2009 [suppl.; abstr. 8001].
  49. Ramalingam S, Belani C. Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions. Oncologist. 2008;13:5–13
  50. NCI launches first-ever study to determine if biomarkers can help guide treatment for lung cancer. http://www.nih.gov/news/health/oct2008/nci-02.htm. Accessed September 28, 2009.
  51. Bell DW, Lynch TJ, Haserlat SM, Harris PL, Okimoto RA, Brannigan BW, et al. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol. 2005;23:8081–8092
  52. Giaccone G, Iacona RB, Fandi A, Janas M, Ochs JS, Herbst RS, et al. Epidermal growth factor receptor expression analysis in chemotherapy-naïve patients with advanced non-small-cell lung cancer treated with gefitinib or placebo in combination with platinum-based chemotherapy. J Cancer Res Clin Oncol. 2008;September 12 [Epub ahead of print]
  53. Gatzemeier U, Pluzanska A, Szczesna A, Kaukel E, Roubec J, De Rosa F, et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol. 2007;25:1545–1552
  54. Gatzemeier U, Heller A, Foernzler D, Moecks J, Ward C, de Rosa F, et al. Exploratory analyses EGFR, kRAS mutations and other molecular markers in tumors of NSCLC patients (pts) treated with chemotherapy±erlotinib (TALENT). J Clin Oncol. 2005;23:627s;[suppl.; abstr. 7028]
  55. Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A, et al. TRIBUTE Investigator Group. TRIBUTE: a phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2005;23:5892–5899
  56. Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non–small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol. 2005;23:5900–5909
  57. Hirsch FR, Varella-Garcia M, Dziadziuszko R, Xiao Y, Gajapathy S, Skokan M, et al. Fluorescence in situ hybridization subgroup analysis of TRIBUTE, a phase III trial of erlotinib plus carboplatin and paclitaxel in non-small cell lung cancer. Clin Cancer Res. 2008;14:6317–6323
  58. Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J, et al. Erlotinib in lung cancer: molecular and clinical predictors of outcome. N Engl J Med. 2005;353:133–144
  59. Zhu CQ, da Cunha Santos G, Ding K, Sakurada A, Cutz JC, Liu N, et al. Role of KRAS and EGFR As biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol. 2008;26:4268–4275
  60. Hirsch FR, Varella-Garcia M, Bunn PA, Franklin WA, Dziadziuszko R, Thatcher N, et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol. 2006;24:5034–5042
  61. Douillard J, Hirsh V, Mok TS, Socinski MA, Watkins C, Lowe E, et al. Molecular and clinical subgroup analyses from a phase III trial comparing gefitinib with docetaxel in previously treated non-small cell lung cancer (INTEREST). J Clin Oncol. 2008;26:[May 20 suppl.; abstr. 8001]
  62. Mok T, Wu YL, Thongprasert S, Yang CH, Chu D, Saijo N, et al. Phase III, randomised, open-label, first-line study of gefitinib vs. carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer. Ann Oncol 2008; 19 (suppl. 8): viii1—Abstract Book of the 33rd European Society of Medical Oncology Congress, Stockholm, Sweden 12–16 September 2008 [abstr. LBA2].
  63. Brugger W, Kim JH, Hansen O, Sullivan R, White S, Lee JS, et al., on behalf of the SATURN investigators. Molecular markers and clinical outcome with erlotinib: results from the phase III placebo-controlled SATURN study of maintenance therapy for advanced NSCLC. WCLC 2009—13th World Conference on Lung Cancer, abstract no. B9.1. J Thorac Oncol 2009; 4(9):S5–S968.
  64. Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, et al. FLEX Study Team. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet. 2009;373:1525–1531
  65. Cobo M, Isla D, Massuti B, Montes A, Sanchez JM, Provencio M, et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol. 2007;25:2747–2754
  66. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26:3543–3551
  67. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004;22:1589–1597
  68. Niho S, Ichinose Y, Tamura T, Yamamoto N, Tsuboi M, Nakagawa K, et al. Results of a randomized Phase III study to compare the overall survival of gefitinib (IRESSA) versus docetaxel in Japanese patients with non-small-cell lung cancer who failed one or two chemotherapy regimens. J Clin Oncol 2007 ASCO Annual Meeting Proceedings Part I. vol. 25, No. 18S (June 20 Supplement): LBA7509.
  69. Gridelli C, Butts C, Ciardiello F, Feld R, Gallo C, Perrone F. An international, multicenter, randomized phase III study of first-line erlotinib followed by second-line cisplatin/gemcitabine versus first-line cisplatin/gemcitabine followed by second-line erlotinib in advanced non-small-cell lung cancer: treatment rationale and protocol dynamics of the TORCH trial. Clin Lung Cancer. 2008;9:235–238
  70. Garattini S, Bertele’ V. Non-inferiority trials are unethical because they disregard patients’ interests. Lancet. 2007;370:1875–1877

PII: S0169-5002(09)00499-1

doi: 10.1016/j.lungcan.2009.10.001

Lung Cancer
Volume 67, Issue 2 , Pages 127-135 , February 2010

Article Tools

* Image Usage & Resolution